File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/sj.bjp.0704179
- Scopus: eid_2-s2.0-0034883504
- PMID: 11487523
- WOS: WOS:000170427900022
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity
Title | Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity |
---|---|
Authors | |
Keywords | 1400W Alzheimer's disease Carboxy-PTIO N-iminoethyl-L-lysine Oxidative stress S-methyl-L-thiocitulline Trolox |
Issue Date | 2001 |
Publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1 |
Citation | British Journal Of Pharmacology, 2001, v. 133 n. 7, p. 1114-1124 How to Cite? |
Abstract | 1. Beta amyloid (Aβ) is implicated in Alzheimer's disease (AD). Aβ 1-42 (5, 10, or 20 μM) was able to increase NO release and decrease cellular viability in primary rat cortical mixed cultures. 2. L-NOARG and SMTC (both at 10 or 100 μM) - type I NOS inhibitors - reduced cellular NO release in the absence of Aβ 1-42. At 100 μM, both drugs decreased cell viability. 3. L-NIL (10 or 100 μM), and 1400W (1 or 5 μM) - type II NOS inhibitors - reduced NO release and improved viability when either drug was administered up to 4 h post Aβ 1-42 (10 μM) treatment. L-NOARG and SMTC (both at 10 or 100 μM) were only able to decrease NO release. Carboxy-PTIO or Trolox (both at 10 or 100 μM) - a NO scavenger and an antioxidant, respectively-increased viability when administered up to 1 h post Aβ 1-42 treatment. Either L-NIL (50 μM) or 1400W (3 μM) and Trolox (50 μM) showed synergistic actions. 4. Peroxynitrite (100 or 200 μM) reduced cell viability. Viabilities were improved by L-NIL (100 μM), 1400W (5 μM), carboxy-PTIO (10 or 100 μM), and Trolox (10 or 100 μM). 5. Hence, the data show that Aβ 1-42 induced NO release in neurons and glial cells, and that Aβ neurotoxicity is, at least in part, mediated by NO. NO concentration modulating compounds and antioxidant may have therapeutic importance in neurological disorders where oxidative stress is likely involved such as in AD. |
Persistent Identifier | http://hdl.handle.net/10722/171902 |
ISSN | 2023 Impact Factor: 6.8 2023 SCImago Journal Rankings: 2.119 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Law, A | en_US |
dc.contributor.author | Gauthier, S | en_US |
dc.contributor.author | Quirion, R | en_US |
dc.date.accessioned | 2012-10-30T06:18:19Z | - |
dc.date.available | 2012-10-30T06:18:19Z | - |
dc.date.issued | 2001 | en_US |
dc.identifier.citation | British Journal Of Pharmacology, 2001, v. 133 n. 7, p. 1114-1124 | en_US |
dc.identifier.issn | 0007-1188 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171902 | - |
dc.description.abstract | 1. Beta amyloid (Aβ) is implicated in Alzheimer's disease (AD). Aβ 1-42 (5, 10, or 20 μM) was able to increase NO release and decrease cellular viability in primary rat cortical mixed cultures. 2. L-NOARG and SMTC (both at 10 or 100 μM) - type I NOS inhibitors - reduced cellular NO release in the absence of Aβ 1-42. At 100 μM, both drugs decreased cell viability. 3. L-NIL (10 or 100 μM), and 1400W (1 or 5 μM) - type II NOS inhibitors - reduced NO release and improved viability when either drug was administered up to 4 h post Aβ 1-42 (10 μM) treatment. L-NOARG and SMTC (both at 10 or 100 μM) were only able to decrease NO release. Carboxy-PTIO or Trolox (both at 10 or 100 μM) - a NO scavenger and an antioxidant, respectively-increased viability when administered up to 1 h post Aβ 1-42 treatment. Either L-NIL (50 μM) or 1400W (3 μM) and Trolox (50 μM) showed synergistic actions. 4. Peroxynitrite (100 or 200 μM) reduced cell viability. Viabilities were improved by L-NIL (100 μM), 1400W (5 μM), carboxy-PTIO (10 or 100 μM), and Trolox (10 or 100 μM). 5. Hence, the data show that Aβ 1-42 induced NO release in neurons and glial cells, and that Aβ neurotoxicity is, at least in part, mediated by NO. NO concentration modulating compounds and antioxidant may have therapeutic importance in neurological disorders where oxidative stress is likely involved such as in AD. | en_US |
dc.language | eng | en_US |
dc.publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1 | en_US |
dc.relation.ispartof | British Journal of Pharmacology | en_US |
dc.subject | 1400W | - |
dc.subject | Alzheimer's disease | - |
dc.subject | Carboxy-PTIO | - |
dc.subject | N-iminoethyl-L-lysine | - |
dc.subject | Oxidative stress | - |
dc.subject | S-methyl-L-thiocitulline | - |
dc.subject | Trolox | - |
dc.subject.mesh | Amyloid Beta-Peptides - Toxicity | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antioxidants - Pharmacology | en_US |
dc.subject.mesh | Benzoates - Pharmacology | en_US |
dc.subject.mesh | Cell Survival - Drug Effects | en_US |
dc.subject.mesh | Cells, Cultured | en_US |
dc.subject.mesh | Cerebral Cortex - Cytology - Drug Effects - Metabolism | en_US |
dc.subject.mesh | Chromans - Pharmacology | en_US |
dc.subject.mesh | Citrulline - Analogs & Derivatives - Pharmacology | en_US |
dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
dc.subject.mesh | Enzyme Inhibitors - Pharmacology | en_US |
dc.subject.mesh | Imidazoles - Pharmacology | en_US |
dc.subject.mesh | Isoenzymes - Antagonists & Inhibitors | en_US |
dc.subject.mesh | Lysine - Analogs & Derivatives - Pharmacology | en_US |
dc.subject.mesh | Neuroprotective Agents - Pharmacology | en_US |
dc.subject.mesh | Nitrates - Pharmacology | en_US |
dc.subject.mesh | Nitric Oxide - Antagonists & Inhibitors - Metabolism | en_US |
dc.subject.mesh | Nitric Oxide Synthase - Antagonists & Inhibitors | en_US |
dc.subject.mesh | Nitroarginine - Pharmacology | en_US |
dc.subject.mesh | Oxidants - Pharmacology | en_US |
dc.subject.mesh | Peptide Fragments - Toxicity | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, Sprague-Dawley | en_US |
dc.subject.mesh | Thiourea - Analogs & Derivatives - Pharmacology | en_US |
dc.subject.mesh | Time Factors | en_US |
dc.title | Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity | en_US |
dc.type | Article | en_US |
dc.identifier.email | Law, A:acklaw@hku.hk | en_US |
dc.identifier.authority | Law, A=rp00262 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1038/sj.bjp.0704179 | - |
dc.identifier.pmid | 11487523 | - |
dc.identifier.scopus | eid_2-s2.0-0034883504 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0034883504&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 133 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.spage | 1114 | en_US |
dc.identifier.epage | 1124 | en_US |
dc.identifier.isi | WOS:000170427900022 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Law, A=26323772800 | en_US |
dc.identifier.scopusauthorid | Gauthier, S=7102604782 | en_US |
dc.identifier.scopusauthorid | Quirion, R=7202416940 | en_US |
dc.identifier.issnl | 0007-1188 | - |